Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care - PubMed
7 hours ago
- #pirtobrutinib
- #CLL
- #BTK inhibitor
- Pirtobrutinib is a highly selective, reversible (noncovalent) BTK inhibitor that inhibits BTK independently of C481 mutations.
- In relapsed/refractory CLL, pirtobrutinib showed improved progression-free survival and time to next treatment compared to idelalisib/rituximab or bendamustine/rituximab.
- Phase III trials suggest pirtobrutinib's superiority over chemoimmunotherapy in untreated patients and non-inferiority to ibrutinib in untreated or cBTKi-naive R/R CLL.
- Current data support potential repositioning of pirtobrutinib from R/R CLL to earlier lines of therapy, though not yet sufficient to change clinical practice.
- The review discusses trial strengths/limitations, frontline noncovalent BTK inhibition rationale, sequencing trade-offs, and future combination strategies.